Announcement PDF Resonance Health Limited Appendix 4E Preliminary final report 1. Company details Name of entity: Resonance Health Limited ABN: 96 006 762 492 Reporting period: For the year ended 30 June 2026 Previous period: For the year ended 30 June 2025 2. Results for announcement to the market 2026 2025 Change Change $ $ $ % Revenues from ordinary activities 15,751,909 11,073,018 4,678,891 42% Profit/(Loss) from ordinary activities after tax attributable to the owners of Resonance Health Limited 1,513,109 (1,732,939) 3,246,048 n/a Profit/(Loss) for the year attributable to the owners of Resonance Health Limited 1,513,109 (1,732,939) 3,246,048 n/a 2026 2025 Cents Cents Basic profit/(loss) per share 0.32 (0.38) Diluted profit/(loss) per share 0.31 (0.38) Dividends There were no dividends paid, recommended or declared during the current financial period. Comments The profit for the Group after providing for income tax amounted to $1,513,109 (30 June 2025: $1,732,939 loss). 3. Net tangible assets Reporting period Previous period Cents Cents Net tangible assets per ordinary security 0.12 (0.22) 4. Control gained over entities Not applicable. 5. Loss of control over entities Not applicable. 6. Dividends Current period There were no dividends paid, recommended or declared during the current financial period. Resonance Health Limited Appendix 4E Preliminary final report Previous period There were no dividends paid, recommended or declared during the previous financial period. 7. Dividend reinvestment plans Not applicable. 8. Details of associates and joint venture entities Not applicable. 9. Foreign entities Details of origin of accounting standards used in compiling the report: Not applicable. 10. Audit qualification or review Details of audit/review dispute or qualification (if any): The financial statements have been audited and an unmodified opinion has been issued. 11. Attachments Details of attachments (if any): The Annual Report of Resonance Health Limited for the year ended 30 June 2026 is attached. 12. Signed Signed ___________________________ Date: 27 August 2026 Mr Aaron Brinkworth Chair Perth, Western Australia Resonance Health Limited ABN 96 006 762 492 Annual Report - 30 June 2026 Resonance Health Limited Chair’s letter to shareholders 30 June 2026 1 Dear Fellow Shareholders, On behalf of the Board of Directors, I am pleased to present the 2026 Annual Report for Resonance Health Ltd (ASX: RHT). A year ago, my predecessor wrote to you that FY25 had been one of the most significant years in the company’s history. FY26 was, by any fair measure, better: it was the year in which our strategy proved itself, with the group profitable, cash- generative and growing across all three of its businesses. Group revenue rose 42% to $15.8 million, and normalised EBITDA of $2.6 million comfortably exceeded the $2.0 million the company originally guided the market to expect — guidance we were pleased to upgrade during the year and then surpass. Net profit after tax of $1.5 million represented a turnaround of more than $3.3 million on the prior year. Of equal importance to your Board, the quality of these earnings was high. Cash receipts reached a record $14.3 million, operating cash flow of $2.9 million was positive in every quarter, and the company closed the year with $4.8 million in cash against $2.5 million of bank debt. This growth was funded from our own operations — the discipline your Board regards as the truest test of our business model. Andrew’s letter describes the operational drivers of the year in detail, so I will confine myself to the matters that most occupy the Board. Resonance Health now operates a genuinely integrated platform — FDA-cleared imaging software, a full- service CRO and a profitable investigator-site network — with each business reinforcing the others, and all three aligned to the same structural forces: the rising prevalence of liver disease, newly approved MASH therapies that depend on imaging, and the rapid growth of GLP-1 clinical trials. Along with financial discipline, your Board is equally focused on risk. The successful conclusion of our major MASH trial makes replacing that revenue the company’s key near-term priority, and the renewal of our NAB facility, which matures in March 2027, will be addressed well ahead of time. Both matters are under active Board oversight. The liver fibrosis device — the largest single opportunity before the company — continues to be developed prudently from our own cash flow, with no revenue from it assumed in our near term plans. During the year I had the honour of succeeding Dr Martin Blake as Chair. On behalf of the Board and all shareholders, I thank Martin for his dedicated stewardship through an important period in the company’s development. We extended the Board’s expertise in April 2026 with the appointments of Dr David Fuller, a physician and pharmacist with three decades of international drug development experience, and Michael Sistenich, whose background spans healthcare investment banking and funds management. Their expertise maps directly onto the decisions ahead of us — clinical, regulatory and capital. We continue to hold the company to high standards of governance, quality and disclosure: from our ISO 13485 certification and FDA, EU MDR and TGA clearances, through to transparent engagement with shareholders via our InvestorHub platform and regular market updates. Our priorities for FY27 are straightforward: convert a record pipeline — including more than $12 million of SaMD orders and bids, and multiple CRO opportunities under review — into contracted revenue; deliver the fibrosis study readout and progress the device toward investigational use in pharmaceutical trials; and allow our automation investments to do their work on margins. Where opportunities to expand our site network or geographic footprint meet our criteria, we will pursue them with discipline. On behalf of the Board, I thank Andrew Harrison and the entire executive and operational team for a year of exceptional execution; my fellow Directors for their counsel; and you, our shareholders, for your continued support. FY26 demonstrated that Resonance Health can deliver strong, profitable growth simultaneously. The Board's focus now is repeating that performance at greater scale in the years ahead, a task we approach with confidence. Mr Aaron Brinkworth Chair Resonance Health Limited CEO's letter to shareholders 30 June 2026 2 Dear Fellow Shareholders, One year ago I described FY25 as a defining year. FY26, I am pleased to report, was a proving year. For sometime the question hanging over Resonance Health has been a simple one: could a company built on world-class imaging science also become a genuinely good business? This year, we answered in the affirmative. Our company earned revenue of $15.8 million, up 42% on the prior year, and delivered normalised EBITDA of $2.6 million. We began the year telling the market to expect $2.0 million in normalised EBITDA, upgraded that guidance as the year unfolded, and then finished ahead of the upgrade — the right order of events, and one we will try to make a habit. Net profit after tax was $1.5 million, a turnaround of more than $3.3 million on FY25. Better still, the profit was made of real money: operations generated $2.9 million of cash, we were cash-flow positive in every quarter of the year, and we closed with $4.8 million in the bank against $2.5 million of debt. Revenue has more than tripled since FY23. Profits are pleasing; cash in the bank is the proof. In these letters I intend to hold myself to the same standard we apply to our clinical work: say what you will do, then measure what you did. Last year I set out four priorities for FY26. Here is the scorecard. First, I said we would realise the full-year benefit of our expanded TrialsWest footprint. TrialsWest revenue rose 56% to $4.1 million1 . Osborne Park, in only its second year, delivered $1.6 million of revenue — ahead of its ramp-up plan — and Mandurah, opened in July 2025, finished its first year close to breakeven, ahead of our expectations. Our three purpose- built sites now serve more than twenty active trials for sponsors including GSK, Pfizer, Novartis, Sanofi and MSD. Second, I said we would expand the Resonance Clinical pipeline. Cumulative CRO contract wins now stand at $20.1 million — a business built from a standing start in under three years — and in April 2026 we completed recruitment of all sixty patients on our $13.8 million MASH trial. Third, I said we would keep innovating within our SaMD portfolio. We brought our VAT/SAT body-composition service to market, scaled our MRE liver-stiffness reads, secured new clinical trial contracts alongside extensions from a number of global blue chip pharma companies, and commenced working with customers to introduce the Resonance Bridge, our secure PACS-integrated workflow, into the imaging network. Clinical trial imaging revenue grew 88%3 as a result. Fourth, I said we would complete the Extended Proof-of-Concept study for our MRI Liver Fibrosis device. Here I will award us nine marks out of ten: enrolment is complete, and the analysis readout is expected early in FY27. More on why that matters below. I would love to tell you these results reflect managerial brilliance. The plainer truth is that a very good team executed well into three powerful tailwinds: the rising global prevalence of liver disease; newly approved MASH therapies, which need imaging to diagnose and monitor patients; and a wave of GLP-1 trials that must measure precisely the things our devices measure. Tailwinds, however, only help the ship that has spent twenty years being built. Resonance Health is usually described as three businesses: Resonance Imaging, our portfolio of FDA-cleared SaMD analysis products; Resonance Clinical, our contract research organisation; and TrialsWest, our investigator site network. I would encourage you to think of them instead as three oars in the same boat. When Resonance Clinical wins a trial, TrialsWest recruits and cares for its patients, and Resonance Imaging analyses its scans. A contract is won once and earned three times. You can see the flywheel in this year’s numbers. Imaging clinical-trial revenue grew 88%1 , CRO revenue grew 81% on the back of the MASH trial, and TrialsWest grew 56%1 — and a meaningful share of each was generated by the other two. That internal referral engine is the asset I want you to understand. Every honest annual letter includes the things that did not go to plan, here are ours. 1 Revenue before intercompany eliminations Resonance Health Limited CEO's letter to shareholders 30 June 2026 3 In June we reset the budget of the MASH trial to reflect slower-than-planned recruitment and a higher screen-failure rate — familiar frustrations in MASH studies, where many patients turn out not to meet the strict entry criteria. This budget reset reduced the gross margin expected to be derived through the trial. Nevertheless, the trial still contributed significantly to EBITDA in FY26, recruitment is complete, and milestone invoicing continues into FY27. Second, the approaching completion of that trial creates our most important near-term task: replacing its revenue. Multiple new CRO opportunities are under active review and our SaMD order-and-bid pipeline finished the year at a record level above $12 million, but I will not describe that job as done until contracts are signed. Third, commercial diagnostics revenue was flat. We aim to address this as we work toward insurance reimbursement for some of our devices. Finally, our $2.5 million NAB facility matures in March 2027. With net cash of $2.3 million and the cash generation noted above, we will address the renewal well ahead of time. During the year we shared with investors an ambition we call Project 50:28 — to grow from roughly $16 million of revenue to $50 million by the end of FY28. Ambitions are cheap; the reason I am willing to publish this aspiration is that every dollar of the growth required is tied to a driver we can name. Two of those drivers deserve a special word. Resonance Bridge, together with the AI-assisted automation tools now in development, targets a five-to-ten-fold increase in analysis capacity without a matching increase in headcount. When the marginal cost of the next scan approaches zero, revenue growth falls largely to the bottom line — which is how we intend to reach EBITDA margins of around 25% at roughly $30 million of revenue. And the MRI Liver Fibrosis device remains the largest single option in our portfolio. Liver biopsy — invasive, costly, and prone to sampling error — is the bottleneck of a large hepatic fibrosis market. Our multi-parametric MRI approach is designed to neutralise the confounders of iron, fat and inflammation that can defeat existing alternatives. With enrolment complete in our Extended Proof of Concept study, we are targeting investigational use in pharmaceutical trials from FY27/28 and commercial clearance beyond that. Development is funded from operating cash flow, and not one dollar of fibrosis revenue sits in FY26 performance. If it succeeds, it is all upside. In April 2026 we strengthened the Board with the appointments of Dr David Fuller, a physician and pharmacist with three decades in drug development, and Michael Sistenich, who brings deep experience in healthcare, technology, and capital markets. Their counsel is already proving invaluable as we assess the growth options in front of us. Behind every number in this letter sit our people: analysts who read close to ten thousand scans this year without compromising on quality, site teams who cared for patients across more than twenty trials, and a clinical team that delivered the largest study in our history. A culture that marries scientific rigour with commercial discipline is the one asset a competitor cannot buy, and ours has never been stronger. A year ago, I wrote that I was confident FY26 would see us take great strides. It did. But I would ask you to judge us the way we judge ourselves: over years, not quarters. The tailwinds at our back are structural rather than cyclical, the platform is profitable, and the opportunity in front of us is far larger than anything behind. Your Board and management think about this business the way owners do, because that is what we are. Thank you — our employees, clinicians, partners and you, our fellow shareholders — for your continued trust. We intend to keep earning it. Andrew Harrison Managing Director & Chief Executive Officer Resonance Health Limited Contents 30 June 2026 4 Corporate directory 5 Directors' report 6 Auditor's independence declaration 25 Consolidated statement of profit or loss and other comprehensive income 26 Consolidated statement of financial position 27 Consolidated statement of changes in equity 28 Consolidated statement of cash flows 29 Notes to the consolidated financial statements 30 Consolidated entity disclosure statement 63 Directors' declaration 64 Independent auditor's report to the members of Resonance Health Limited 65 Shareholder information 69 Resonance Health Limited Corporate directory 30 June 2026 5 Directors Mr Aaron Brinkworth - Non-executive Chair Mr Andrew Harrison – Managing Director and Chief Executive Officer Mr Mitchell Wells - Non-executive Director & Company Secretary Mr Simon Panton - Non-executive Director Dr Travis Baroni - Non-executive Director Dr David Fuller - Non-executive Director Mr Michael Sistenich - Non-executive Director Registered office Level 1 141 Burswood Road BURSWOOD WA 6100 T: +61 8 9286 5300 F: +61 8 9286 5399 Principal place of business Level 1 141 Burswood Road BURSWOOD WA 6100 T: +61 8 9286 5300 F: +61 8 9286 5399 Share register Automic Group Level 5, 191 St Georges Terrace Perth WA 6000 Telephone: 1300 288 664 Auditor HLB Mann Judd Level 4 130 Stirling Street Perth WA 6000 Solicitors Steinepreis Paganin Level 4, The Reed Building 16 Milligan Street Perth WA 6000 Bankers National Australia Bank Limited Stock exchange listing Resonance Health Limited shares are listed on the Australian Securities Exchange (ASX) (ASX code: RHT) Websites www.resonancehealth.com www.trialswest.com.au email: info@resonancehealth.com Resonance Health Limited Directors' report 30 June 2026 6 The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group' or ‘Resonance Health’) consisting of Resonance Health Limited (referred to hereafter also as the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2026. Directors The following persons were Directors of Resonance Health Limited during the whole of the financial year and up to the date of this report, unless otherwise stated: Dr Martin Blake – Resigned 13 November 2025 Mr Mitchell Wells Mr Simon Panton Dr Travis Baroni Mr Aaron Brinkworth Dr David Fuller – Appointed 28 April 2026 Mr Michael Sistenich – Appointed 28 April 2026 Mr Andrew Harrison – Transitioned to Managing Director 1 October 2025 Principal activities The Group’s business was founded on the development and commercialisation of software-as-medical-device (‘SaMD’) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group’s core SaMD product is FerriScan®, a non-invasive liver analysis technology used for the assessment of iron in the liver. Other Company SaMDs include Cardiac T2*, for the assessment of iron in the heart, and HepaFat-Scan® for the assessment of fat in and around the liver. The Company also has several AI-assisted SaMDs including FerriSmart®, HepaFatSmart, and LiverSmart®. In addition to its SaMD business, the Group operates as the Clinical Trial Research Organisation (CRO) and local sponsor in Australia on one clinical trial for a major global pharma company’s new drug compound. The Group is overseeing aspects of the conduct and delivery of this trial in Australia. In recent years, the Group has further expanded into the clinical trial ecosystem and operates a Site Management Organisation trading as TrialsWest. TrialsWest is a clinical research centre that partners with some of the world’s leading pharmaceutical and biotechnology companies to help bring new medicines and vaccines to the global community. Specifically, TrialsWest has three trial sites based in and around Perth, Western Australia and offers site management services to the clinical trial market specializing in the delivery of clinical trials in the community. Dividends There were no dividends paid, recommended or declared during the current or previous financial year. Review of operations The profit for the Group after providing for income tax amounted to $1,513,109 (30 June 2025 $1,732,939 loss). Contributing to this result the Group is an income tax benefit of $413,631 which was the net difference between the Group’s Research and Development (R&D) tax incentive refund for R&D performed in the FY2025 year totaling $832,959, the total amount of income taxation payable by the Group given its FY2025 financial performance totaling $100,108, the expected income tax payable for FY26 of $459,293 and recognition of deferred tax assets of $115,598. The Group continues to invest in R&D, business development, regulatory and quality affairs, and customer service capabilities to both develop and monetise its technologies and other services globally. Resonance Health Limited Directors' report 30 June 2026 7 Cash at bank as at 30 June 2026 totalled $4.85 million, in comparison to the 30 June 2025 cash balance of $2.98 million. The Group has $2.53m of debt in the form of a secured financing facility, which was used to finance the acquisition of TrialsWest Pty Ltd in previous years. About Resonance Health Resonance Health Limited is an Australian healthcare technology and services company. The Group's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development. Resonance Health’s dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (SaMDs) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (AI), include: ● FerriScan® , a core-lab product that provides an accurate assessment of liver iron concentration (LIC) through non- invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment. ● FerriSmart® , an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in patients, calibrated against the global gold standard, FerriScan® . ● HepaFatScan® , an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease. ● HepaFatSmart® , an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease. ● LiverSmart® , an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFatSmart ® into a consolidated report providing accurate assessment of LIC and liver fat. ● CardiacT2*, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*. CardiacT2* is TGA and CE Marking regulatory cleared. The Group has a development pipeline of additional medical imaging analysis products and services, including the MRI Liver Fibrosis Project, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis. Sales Revenue Strong demand in clinical trials in particular alongside the continuation of the clinical trial agreement underway with a major global pharma company resulted in sales revenue for the year of $15.8 million, a 42% increase on FY2025 of $11.1 million. Of note, the SaMD business experienced a significant increase in demand for its liver disease related products and new end points recently introduced including a central-read service for Magnetic Resonance Elastography (MRE) and visceral and subcutaneous fat volume quantification (VAT & SAT). This was also reflected in cashflow with net operating cash flow of $2.9M in the period, versus net operating cash flow of $1.2M in FY25, a 130% increase. The Resonance Clinical agreement with a major global pharma company for the delivery of CRO services contributed approximately $7.5 million in revenue in the period and TrialsWest continued to drive greater patient numbers and consolidate the recent expansion of its site network to three sites across Spearwood, Osborne Park and Mandurah. Geographically, North America, Asia Pacific and the UK were our biggest markets, with the balance of sales mostly spread across Europe, Asia, and Australia. Resonance Health Limited Directors' report 30 June 2026 8 Services The Group provides its products and services to customers in both diagnostic and clinical trial settings. During the year its products and services were used in over 244 hospitals and MRI centres around the world. Resonance Health’s analysis reports are an assessment tool used by clinicians when treating patients with chronic iron-overload and fatty-liver diseases. Customers in diagnostic settings accounted for less than 20% of revenues, while clinical trial customers accounted for almost 80% of revenues. Resonance Health continues to actively engage with the global clinical trial market to build on the successful use of its products and services. Due to the highly technical and regulated nature of clinical trial services, revenue from these customers is usually based on multiyear contracts and is higher margin compared to diagnostic customers. Summary of Activities Liver MRI Fibrosis Extended Proof of Concept The Group continues to make progress on its extended proof of concept (EPoC) for a non-invasive MRI Liver Fibrosis assessment. Of note, recruitment on the trial completed during the period and the Group has now received all required MRI and biopsy data for each patient. Analysis of all data is now underway. The results of the EPoC study, if successful, will allow the Group’s continued engagement with pharmaceutical companies developing treatments for chronic liver disease, particularly metabolic dysfunction-associated steatohepatitis (MASH) (formerly known as NASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) (formerly known as NAFLD), to further assess the commercial potential of the technology. Further, the EPoC study where successful is expected to result in the development of a Liver MRI Fibrosis tool which can start to be used in clinical trials (for investigative use only) whilst the product undergoes registration in domestic and foreign markets. International advocacy associations and regulators, including the United States Food & Drug Administration (US FDA) and the LITMUS consortium (Liver Investigation: Testing Marker Utility in Steatohepatitis) in the EU, continue to highlight the urgent need for the development of new, validated, non-invasive biomarkers to assess liver fibrosis to accelerate drug development in the above key areas which are the most common causes of chronic liver disease. Resonance Health Limited Directors' report 30 June 2026 9 Other Product Innovations In addition to Liver MRI Fibrosis, Resonance Health continued to invest in the enhancement of its existing products and the development of new products through its broader research and development program during the financial year. In particular, Resonance Health continues to expand its central-read analysis service offerings to cover more clinical trial imaging endpoints. Consistent with this, the Company recently commenced a central-read service for Magnetic Resonance Elastography (MRE) and visceral and subcutaneous fat volume quantification (VAT & SAT). These endpoints were the source of significant revenue growth in FY26 and are expected to remain highly relevant for international pharma customers and their obesity related clinical trials. In addition, significant focus continued to be placed on the ongoing refinement of the machine learning methodology underpinning FerriSmart® which is expected to offer benefits to customers using this product as well as potentially opening new markets for the product. It is expected that certain elements of this workstream will also offer potential productivity and cost efficiencies in undertaking FerriScan® analysis to allow the Group to significantly increase the number of scans undertaken each year without any material increase in direct cost. Initial testing suggests that the technological refinements may offer the group a 5x - 10x increase in scan volume capability. Finally, the Company continued its development of its new ‘bridge’ technology. This technology has been developed in- house to vastly improve customer experience by allowing more direct integration of Resonance Health’s systems with customers’ picture-archiving and communication-system (PACS) platforms. PACS is used globally in medical fields including radiology practices and MRI centres and the new bridge technology will support more scalable and seamless service delivery to customers. The technology remains in the commercial testing phase and is expected to be more broadly implemented across the Company’s customer network in the coming year. Resonance Clinical & Clinical Trials The Group continued to deliver on its $13.8M clinical trial agreement on behalf of a major global pharma company where it acts as CRO and local sponsor. Under the contract the Group is overseeing aspects of the conduct and delivery of this trial in Australia. This clinical trial agreement generated $7.5M in revenue during the period with the trial expected to complete early in calendar year 2027. This trial represents another major step forward in the Group’s strategy to expand its services in the clinical trial ecosystem and the Group continues to pursue multiple opportunities in respect of future CRO and local sponsor trial engagements in Australia. TrialsWest & Clinical Trials Site Management Services The Group acquired TrialsWest in June 2024 which is a clinical research centre that partners with some of the world’s leading pharmaceutical and biotechnology companies to help bring new medicines and vaccines to the global community. Specifically, TrialsWest offers site management services to the clinical trial market specialising in the delivery of clinical trials in the community. The Group has worked extensively to consolidate and expand the TrialsWest geographical footprint which now consists of three sites across broader metropolitan Perth, WA (with sites now in Spearwood, Osborne Park and Mandurah). Importantly, TrialsWest’s new sites in Osborne Park and Mandurah continued to experience growth in the period and the Spearwood site consistently performed to pre-acquisition levels across the year. TrialsWest’s founders remain in key leadership positions and are actively involved in the business, and it is expected that TrialsWest will continue to be a source of organic and acquisitive growth going forward as the business looks to continue to expand its presence and actively pursue value accretive